Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Structural and Thermodynamic Analysis of the Resistance Development to Pimodivir (VX-787), the Clinical Inhibitor of Cap Binding to PB2 Subunit of Influenza A Polymerase

J. Gregor, K. Radilová, J. Brynda, J. Fanfrlík, J. Konvalinka, M. Kožíšek

. 2021 ; 26 (4) : . [pub] 20210214

Language English Country Switzerland

Document type Journal Article

Grant support
CZ.02.1.01/0.0/0.0/16_019/0000729 European Regional Development Fund; OP RDE; Project: "Chemical biology for drugging undruggable targets (ChemBioDrug)

Influenza A virus (IAV) encodes a polymerase composed of three subunits: PA, with endonuclease activity, PB1 with polymerase activity and PB2 with host RNA five-prime cap binding site. Their cooperation and stepwise activation include a process called cap-snatching, which is a crucial step in the IAV life cycle. Reproduction of IAV can be blocked by disrupting the interaction between the PB2 domain and the five-prime cap. An inhibitor of this interaction called pimodivir (VX-787) recently entered the third phase of clinical trial; however, several mutations in PB2 that cause resistance to pimodivir were observed. First major mutation, F404Y, causing resistance was identified during preclinical testing, next the mutation M431I was identified in patients during the second phase of clinical trials. The mutation H357N was identified during testing of IAV strains at Centers for Disease Control and Prevention. We set out to provide a structural and thermodynamic analysis of the interactions between cap-binding domain of PB2 wild-type and PB2 variants bearing these mutations and pimodivir. Here we present four crystal structures of PB2-WT, PB2-F404Y, PB2-M431I and PB2-H357N in complex with pimodivir. We have thermodynamically analysed all PB2 variants and proposed the effect of these mutations on thermodynamic parameters of these interactions and pimodivir resistance development. These data will contribute to understanding the effect of these missense mutations to the resistance development and help to design next generation inhibitors.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21019249
003      
CZ-PrNML
005      
20210830100828.0
007      
ta
008      
210728s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/molecules26041007 $2 doi
035    __
$a (PubMed)33673017
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Gregor, Jiří $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Gilead Sciences and IOCB Research Center, Flemingovo n. 2, 16610 Prague 6, Czech Republic $u First Faculty of Medicine, Charles University, Kateřinská 1660/32, 12108 Prague 2, Czech Republic
245    10
$a Structural and Thermodynamic Analysis of the Resistance Development to Pimodivir (VX-787), the Clinical Inhibitor of Cap Binding to PB2 Subunit of Influenza A Polymerase / $c J. Gregor, K. Radilová, J. Brynda, J. Fanfrlík, J. Konvalinka, M. Kožíšek
520    9_
$a Influenza A virus (IAV) encodes a polymerase composed of three subunits: PA, with endonuclease activity, PB1 with polymerase activity and PB2 with host RNA five-prime cap binding site. Their cooperation and stepwise activation include a process called cap-snatching, which is a crucial step in the IAV life cycle. Reproduction of IAV can be blocked by disrupting the interaction between the PB2 domain and the five-prime cap. An inhibitor of this interaction called pimodivir (VX-787) recently entered the third phase of clinical trial; however, several mutations in PB2 that cause resistance to pimodivir were observed. First major mutation, F404Y, causing resistance was identified during preclinical testing, next the mutation M431I was identified in patients during the second phase of clinical trials. The mutation H357N was identified during testing of IAV strains at Centers for Disease Control and Prevention. We set out to provide a structural and thermodynamic analysis of the interactions between cap-binding domain of PB2 wild-type and PB2 variants bearing these mutations and pimodivir. Here we present four crystal structures of PB2-WT, PB2-F404Y, PB2-M431I and PB2-H357N in complex with pimodivir. We have thermodynamically analysed all PB2 variants and proposed the effect of these mutations on thermodynamic parameters of these interactions and pimodivir resistance development. These data will contribute to understanding the effect of these missense mutations to the resistance development and help to design next generation inhibitors.
650    _2
$a krystalografie rentgenová $7 D018360
650    _2
$a virová léková rezistence $x účinky léků $7 D024882
650    _2
$a virus chřipky A $x účinky léků $x enzymologie $7 D009980
650    _2
$a molekulární modely $7 D008958
650    _2
$a mutantní proteiny $x metabolismus $7 D050505
650    _2
$a mutace $x genetika $7 D009154
650    _2
$a proteinové domény $7 D000072417
650    _2
$a podjednotky proteinů $x antagonisté a inhibitory $x chemie $x metabolismus $7 D021122
650    _2
$a pyridiny $x chemie $x farmakologie $7 D011725
650    _2
$a pyrimidiny $x chemie $x farmakologie $7 D011743
650    _2
$a pyrroly $x chemie $x farmakologie $7 D011758
650    _2
$a kvantová teorie $7 D011789
650    _2
$a RNA-dependentní RNA-polymerasa $x antagonisté a inhibitory $x chemie $x metabolismus $7 D012324
650    _2
$a termodynamika $7 D013816
650    _2
$a virové proteiny $x antagonisté a inhibitory $x chemie $x metabolismus $7 D014764
655    _2
$a časopisecké články $7 D016428
700    1_
$a Radilová, Kateřina $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Gilead Sciences and IOCB Research Center, Flemingovo n. 2, 16610 Prague 6, Czech Republic $u First Faculty of Medicine, Charles University, Kateřinská 1660/32, 12108 Prague 2, Czech Republic
700    1_
$a Brynda, Jiří $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Gilead Sciences and IOCB Research Center, Flemingovo n. 2, 16610 Prague 6, Czech Republic
700    1_
$a Fanfrlík, Jindřich $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Gilead Sciences and IOCB Research Center, Flemingovo n. 2, 16610 Prague 6, Czech Republic
700    1_
$a Konvalinka, Jan $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Gilead Sciences and IOCB Research Center, Flemingovo n. 2, 16610 Prague 6, Czech Republic $u Department of Biochemistry, Faculty of Science, Charles University, Hlavova 8, 12800 Prague 2, Czech Republic
700    1_
$a Kožíšek, Milan $u Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Gilead Sciences and IOCB Research Center, Flemingovo n. 2, 16610 Prague 6, Czech Republic
773    0_
$w MED00180394 $t Molecules (Basel, Switzerland) $x 1420-3049 $g Roč. 26, č. 4 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33673017 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830100828 $b ABA008
999    __
$a ok $b bmc $g 1690143 $s 1139695
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 26 $c 4 $e 20210214 $i 1420-3049 $m Molecules $n Molecules $x MED00180394
GRA    __
$a CZ.02.1.01/0.0/0.0/16_019/0000729 $p European Regional Development Fund; OP RDE; Project: "Chemical biology for drugging undruggable targets (ChemBioDrug)
LZP    __
$a Pubmed-20210728

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...